Kura Oncology announced the publication of preclinical findings for ziftomenib, a drug that received FDA approval in 2025.
1 report, 1 independent
Updated Aug 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kura Oncology announced the publication of preclinical findings for ziftomenib, a drug that received FDA approval in 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Kura Oncology
company in La Jolla, United States
Nothing else this week.
- FDA
-
University of Michigan
public research university in Ann Arbor, Michigan